STEN

Sten Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for life-threatening cardiovascular and pulmonary diseases. The company's primary focus is on the modulation of adenosine signaling through the inhibition of equilibrative nucleoside transporters (ENTs) to enhance endogenous protective mechanisms. Their lead program, STEN-101, is being investigated for the treatment of pulmonary arterial hypertension (PAH) and other conditions characterized by vascular dysfunction. By targeting the ENT1 and ENT2 transporters, Sten Therapeutics aims to provide a more localized and potent therapeutic effect compared to systemic adenosine administration.